欧美一区二区三区精品视频在线,天天碰夜夜爱视频_天天日夜夜操2023_国产午夜亚洲精品一区二区三区_欧美精品成人一区二区三区影院 ,久久久免费精品re6,国产一区二区在线免费观看,日本欧美天天看片在线观看,伊人热热久久原色播放www,久久综合久色综合欧美婷婷,91精品影院一区二区三区,国产99久久精品一区二区 国产一区二区精品推荐 国产女同一区二区三区五区 99av亚洲综合一区二区

  Recently, Dr. Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, led a delegation to visit Cholesgen to discuss their early-stage drug development collaboration. To date, the joint collaboration efforts in early-stage drug development have progressed smoothly and are delivering to plan. During the visit, AstraZeneca recognized the team for the project’s execution, as well as Cholesgen’s R&D capabilities and professional expertise and both parties reviewed the existing collaboration outcomes and discussed potential for further opportunities.

 近日，阿斯利康全球高級副總裁，心血管、腎病及代謝疾病早期研發負責人Regina Fritsche Danielson博士率團訪問珂闌醫藥，就雙方在早期藥物開發領域的合作展開交流。目前雙方在早期藥物開發方面的聯合合作進展順利，按計劃有序推進。

  訪問期間，阿斯利康對項目執行情況、珂闌醫藥的研發實力與專業能力給予了認可；雙方共同回顧了現有合作成果，并探討了未來進一步深化合作的潛在機會。